Recent Updates
Recently added Catalysts
IMMP

Appendix 3Y Change of Director s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen

Key Takeaway: Change of Director s Interest Notice Change of Director s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and may be made public. Introduced 30/9/2001. Name of

Full Press Release Details

Change of Director s Interest Notice
Change of Director s Interest Notice
Information or documents not available now
must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and may be made public.
Introduced 30/9/2001.
Name of Entity: PRIMA BIOMED LIMITED (ASX:PRR)
ACN: 90 009 237 889
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the
purposes of section 205G of the Corporations Act.
Name of Director: Mr Matthew Lehman
Date of Last Notice: 11 April 2013
Part 1 - Change of director s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of notifiable interest of a director should
be disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. N/A
Date of change 12 April 2013
No. of securities held prior to change 1) Ordinary Fully Paid Shares
Shares Options
Direct 1,100,000 1,700,000
Indirect
Total 1,100,000 1,700,000
2) American Depositary Receipts (ADR)
Shares Options
Direct 2,000
Indirect
Total 2,000
Change of Director s Interest Notice
Class 1) Ordinary Fully Paid Shares 2) American Depositary Receipts (ADR) traded on the NASDAQ 1 ADR = 30 ordinary fully paid shares
Number acquired 1) Ordinary Fully Paid Shares
Shares Options
Direct 105,263
Indirect
Total 105,263
2) American Depositary Receipts (ADR)
Shares Options
Direct 500
Indirect
Total 500
Number disposed
Shares Options
Direct
Indirect
Total
Value/Consideration 1) A$ 9,789.46
Note: If consideration is non-cash, provide details and estimated valuation 2) US$ 1,625
No. of securities held after change 1) Ordinary Fully Paid Shares
Shares Options
Direct 1,205,263 1,700,000
Indirect
Total 1,205,263 1,700,000
2) American Depositary Receipts (ADR)
Shares Options
Direct 2,500
Indirect
Total 2,500
Change of Director s Interest Notice
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back 1) Acquiring 105,263 fully paid ordinary shares on market at $0.093 each.
2) Acquiring 500 ADR s at US$3.25 each that are traded on the NASDAQ
Part 2 Change of director s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of notifiable interest of a director should
be disclosed in this part.
Detail of contract N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Part 3 - +Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided on what date was this provided?
Last updated: Apr 12, 2013